go-v.orgdoi

Safety and outcomes of volumetric modulated arc therapy in the treatment of patients with inoperable lung cancer

Xiance Jin, Baochai Lin, Didi Chen, Lili Li, Ce Han, Yongqiang Zhou, Xiaomin Zheng, Changfei Gong, Mengfeng Chen, Congying Xie · Journal of Cancer · 2019

  • DOI 10.7150/jca.31260
  • Publisher Ivyspring International Publisher
  • Type article
  • Issued 2019

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of Cancer · Ivyspring International Publisher · article · 2019

Abstract

Background: Published data on the effects and toxicities of volumetric modulated arc therapy (VMAT) in the management of inoperable lung cancer are scarce.

Materials and methods:The clinical outcomes and pulmonary toxicities of 134 patients with consecutive inoperable lung cancer who underwent VMAT from March 2011 to September 2016 were retrospectively reviewed.The dosimetric and characteristic factors associated with acute radiation pneumonitis (RP) and pulmonary fibrosis were evaluated with univariate and multivariate analysis.Results: The average prescription doses to these 134 patients were 57.07±6.27Gy (range 52-64 Gy).The overall median follow-up time was 18.6 months (range, 2-45 mo), with a median follow-up time for the surviving patients of 20 months (range, 7-45 mo).The 2-year progression-free survival (PFS) and overall survival (OS) for all patients were 18.2% and 38.4%, with a median PFS and OS of 7.6 months and 18.6 months, respectively.The percent of patients with grade III/higher RP and pulmonary fibrosis were 10.5% and 9.0%, respectively.V13 (p=0.02) and age (p=0.02) were independently associated with acute RP according to multivariate analysis.The constraints for lung dosimetric metrics V10,V13,V20 and V30 were approximately 49%,41%,26% and 17% in VMAT treatment of lung cancer to limit the RP rate < 10%.Conclusion: VMAT can be delivered safely with acceptable acute and late toxicities for lung cancer patients.Lung dosimetric metrics were valuable in predicting acute RP.A lung V13 constraint of 40% was helpful to limit the RP rate < 10% in VMAT treatment of lung cancer patients.

Open the resolved locator · 10.7150/jca.31260

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 21:36 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.jcancer.org/v10p2868.htm
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.